Quick Answer
Upstream Bio, Inc. reported Total Revenue of $2.85 million for fiscal year 2025.
Upstream Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $2.85M +20.4% |
$2.37M -0.4% |
$2.38M | — |
| Revenue (ASC 606) | $2.85M +20.4% |
$2.37M -0.4% |
$2.38M | — |
| Net Income | -$143.44M -128.4% |
-$62.81M -205.8% |
-$20.54M | — |
| Diluted EPS | -$2.66 +52.3% |
-$5.58 +56.9% |
-$12.95 | — |
| Total Assets | $353.77M -26.6% |
$481.72M +311.0% |
$117.20M | — |
| Cash and Equivalents | $101.58M -68.8% |
$325.89M +1161.5% |
$25.83M | — |
| Stockholders Equity | $339.77M -27.7% |
$469.85M +481.6% |
-$123.13M -16.0% |
-$106.16M |
| R&D Expense | $136.81M +117.3% |
$62.97M +98.0% |
$31.80M | — |
| Operating Income | -$160.36M -106.2% |
-$77.76M -93.9% |
-$40.11M | — |
| Shares Outstanding | 54.24M +1.2% |
53.60M +1691.3% |
2.99M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $683.0K | +12.5% | -27.1% |
| Revenue (ASC 606) | September 30, 2025 | $683.0K | +12.5% | -27.1% |
| Net Income | September 30, 2025 | -$33.75M | -111.0% | +15.6% |
| Diluted EPS | September 30, 2025 | -$0.63 | +90.9% | +14.9% |
| Total Assets | September 30, 2025 | $391.19M | +68.1% | -7.0% |
| Cash and Equivalents | September 30, 2025 | $72.16M | +119.0% | +58.7% |
| Stockholders Equity | September 30, 2025 | $378.58M | +336.2% | -7.4% |
| R&D Expense | September 30, 2025 | $32.98M | +113.7% | -12.9% |
| Operating Income | September 30, 2025 | -$37.83M | -100.3% | +14.7% |
| Shares Outstanding | September 30, 2025 | 54.00M | +1684.8% | +0.4% |
- Upstream Bio, Inc. reported Total Revenue of $2.85 million for fiscal year 2025.
- Upstream Bio, Inc. showed an increase of +20.4% in Total Revenue compared to the prior fiscal year.
- Upstream Bio, Inc. reported Revenue (ASC 606) of $2.85 million for fiscal year 2025.
- Upstream Bio, Inc. showed an increase of +20.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Upstream Bio, Inc. reported Net Income of -$143.44 million for fiscal year 2025.
- Upstream Bio, Inc. showed a decrease of -128.4% in Net Income compared to the prior fiscal year.
- Upstream Bio, Inc. reported Diluted EPS of $2.66 per share (loss) for fiscal year 2025.
- Upstream Bio, Inc. showed an increase of +52.3% in Diluted EPS compared to the prior fiscal year.
- Upstream Bio, Inc. reported Total Assets of $353.77 million for fiscal year 2025.
- Upstream Bio, Inc. showed a decrease of -26.6% in Total Assets compared to the prior fiscal year.
- Upstream Bio, Inc. reported Cash and Equivalents of $101.58 million for fiscal year 2025.
- Upstream Bio, Inc. showed a decrease of -68.8% in Cash and Equivalents compared to the prior fiscal year.
- Upstream Bio, Inc. reported Stockholders Equity of $339.77 million for fiscal year 2025.
- Upstream Bio, Inc. showed a decrease of -27.7% in Stockholders Equity compared to the prior fiscal year.
- Upstream Bio, Inc. reported R&D Expense of $136.81 million for fiscal year 2025.
- Upstream Bio, Inc. showed an increase of +117.3% in R&D Expense compared to the prior fiscal year.
- Upstream Bio, Inc. reported Operating Income of -$160.36 million for fiscal year 2025.
- Upstream Bio, Inc. showed a decrease of -106.2% in Operating Income compared to the prior fiscal year.
- Upstream Bio, Inc. reported Shares Outstanding of 54.24 million shares for fiscal year 2025.
- Upstream Bio, Inc. showed an increase of +1.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: